Prostate cancer screening among elderly men in Brazil: should we diagnose or not?

Detalhes bibliográficos
Autor(a) principal: Mori,Rafael Ribeiro
Data de Publicação: 2020
Outros Autores: Faria,Eliney Ferreira, Mauad,Edmundo Carvalho, Rodrigues Jr.,Antonio Antunes, Reis,Rodolfo Borges dos
Tipo de documento: Artigo
Idioma: eng
Título da fonte: International Braz J Urol (Online)
Texto Completo: http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1677-55382020000100034
Resumo: ABSTRACT Purpose: Prostate cancer screening in the elderly is controversial. The Brazilian government and the National Cancer Institute (INCA) do not recommend systematic screening. Our purpose was to assess prevalence and aggressiveness of prostate cancer in men aged 70 years and above, on the first Latin American database to date. Materials and Methods: Cross-sectional study (n=17,571) from 231 municipalities, visited by Mobile Cancer Prevention Units of a prostate-specific antigen (PSA) based opportunistic screening program, between 2004 and 2007. The criteria for biopsy were: PSA>4.0ng/ml, or PSA 2.5-4.0ng/ml with free/total PSA ratio ≤15%, or suspicious digital rectal examination findings. The screened men were stratified in two age groups (45-69 years, and ≥70 years). These groups were compared regarding prostate cancer prevalence and aggressiveness criteria (PSA, Gleason score from biopsy and TNM staging). Results: The prevalence of prostate cancer found was 3.7%. When compared to men aged 45-69 years, individuals aged 70 years and above presented cancer prevalence about three times higher (prevalence ratio 2.9, p<0.01), and greater likelihood to present PSA level above 10.0ng/ml at diagnosis (odds ratio 2.63, p<0.01). The group of elderly men also presented prevalence of histologically aggressive disease (Gleason 8-10) 3.6 times higher (p<0.01), and 5-fold greater prevalence of metastases (PR 4.95, p<0.05). Conclusions: Prostate cancer screening in men aged over 70 may be relevant in Brazil, considering the absence of systematic screening, higher prevalence and higher probability of high-risk disease found in this age range of the population studied.
id SBU-1_fc822e46b8c86cb38bf93f72544ac9a5
oai_identifier_str oai:scielo:S1677-55382020000100034
network_acronym_str SBU-1
network_name_str International Braz J Urol (Online)
repository_id_str
spelling Prostate cancer screening among elderly men in Brazil: should we diagnose or not?Prostatic NeoplasmsEarly Detection of CancerDiagnosisABSTRACT Purpose: Prostate cancer screening in the elderly is controversial. The Brazilian government and the National Cancer Institute (INCA) do not recommend systematic screening. Our purpose was to assess prevalence and aggressiveness of prostate cancer in men aged 70 years and above, on the first Latin American database to date. Materials and Methods: Cross-sectional study (n=17,571) from 231 municipalities, visited by Mobile Cancer Prevention Units of a prostate-specific antigen (PSA) based opportunistic screening program, between 2004 and 2007. The criteria for biopsy were: PSA>4.0ng/ml, or PSA 2.5-4.0ng/ml with free/total PSA ratio ≤15%, or suspicious digital rectal examination findings. The screened men were stratified in two age groups (45-69 years, and ≥70 years). These groups were compared regarding prostate cancer prevalence and aggressiveness criteria (PSA, Gleason score from biopsy and TNM staging). Results: The prevalence of prostate cancer found was 3.7%. When compared to men aged 45-69 years, individuals aged 70 years and above presented cancer prevalence about three times higher (prevalence ratio 2.9, p<0.01), and greater likelihood to present PSA level above 10.0ng/ml at diagnosis (odds ratio 2.63, p<0.01). The group of elderly men also presented prevalence of histologically aggressive disease (Gleason 8-10) 3.6 times higher (p<0.01), and 5-fold greater prevalence of metastases (PR 4.95, p<0.05). Conclusions: Prostate cancer screening in men aged over 70 may be relevant in Brazil, considering the absence of systematic screening, higher prevalence and higher probability of high-risk disease found in this age range of the population studied.Sociedade Brasileira de Urologia2020-02-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S1677-55382020000100034International braz j urol v.46 n.1 2020reponame:International Braz J Urol (Online)instname:Sociedade Brasileira de Urologia (SBU)instacron:SBU10.1590/s1677-5538.ibju.2019.0022info:eu-repo/semantics/openAccessMori,Rafael RibeiroFaria,Eliney FerreiraMauad,Edmundo CarvalhoRodrigues Jr.,Antonio AntunesReis,Rodolfo Borges doseng2020-01-10T00:00:00Zoai:scielo:S1677-55382020000100034Revistahttp://www.brazjurol.com.br/ONGhttps://old.scielo.br/oai/scielo-oai.php||brazjurol@brazjurol.com.br1677-61191677-5538opendoar:2020-01-10T00:00International Braz J Urol (Online) - Sociedade Brasileira de Urologia (SBU)false
dc.title.none.fl_str_mv Prostate cancer screening among elderly men in Brazil: should we diagnose or not?
title Prostate cancer screening among elderly men in Brazil: should we diagnose or not?
spellingShingle Prostate cancer screening among elderly men in Brazil: should we diagnose or not?
Mori,Rafael Ribeiro
Prostatic Neoplasms
Early Detection of Cancer
Diagnosis
title_short Prostate cancer screening among elderly men in Brazil: should we diagnose or not?
title_full Prostate cancer screening among elderly men in Brazil: should we diagnose or not?
title_fullStr Prostate cancer screening among elderly men in Brazil: should we diagnose or not?
title_full_unstemmed Prostate cancer screening among elderly men in Brazil: should we diagnose or not?
title_sort Prostate cancer screening among elderly men in Brazil: should we diagnose or not?
author Mori,Rafael Ribeiro
author_facet Mori,Rafael Ribeiro
Faria,Eliney Ferreira
Mauad,Edmundo Carvalho
Rodrigues Jr.,Antonio Antunes
Reis,Rodolfo Borges dos
author_role author
author2 Faria,Eliney Ferreira
Mauad,Edmundo Carvalho
Rodrigues Jr.,Antonio Antunes
Reis,Rodolfo Borges dos
author2_role author
author
author
author
dc.contributor.author.fl_str_mv Mori,Rafael Ribeiro
Faria,Eliney Ferreira
Mauad,Edmundo Carvalho
Rodrigues Jr.,Antonio Antunes
Reis,Rodolfo Borges dos
dc.subject.por.fl_str_mv Prostatic Neoplasms
Early Detection of Cancer
Diagnosis
topic Prostatic Neoplasms
Early Detection of Cancer
Diagnosis
description ABSTRACT Purpose: Prostate cancer screening in the elderly is controversial. The Brazilian government and the National Cancer Institute (INCA) do not recommend systematic screening. Our purpose was to assess prevalence and aggressiveness of prostate cancer in men aged 70 years and above, on the first Latin American database to date. Materials and Methods: Cross-sectional study (n=17,571) from 231 municipalities, visited by Mobile Cancer Prevention Units of a prostate-specific antigen (PSA) based opportunistic screening program, between 2004 and 2007. The criteria for biopsy were: PSA>4.0ng/ml, or PSA 2.5-4.0ng/ml with free/total PSA ratio ≤15%, or suspicious digital rectal examination findings. The screened men were stratified in two age groups (45-69 years, and ≥70 years). These groups were compared regarding prostate cancer prevalence and aggressiveness criteria (PSA, Gleason score from biopsy and TNM staging). Results: The prevalence of prostate cancer found was 3.7%. When compared to men aged 45-69 years, individuals aged 70 years and above presented cancer prevalence about three times higher (prevalence ratio 2.9, p<0.01), and greater likelihood to present PSA level above 10.0ng/ml at diagnosis (odds ratio 2.63, p<0.01). The group of elderly men also presented prevalence of histologically aggressive disease (Gleason 8-10) 3.6 times higher (p<0.01), and 5-fold greater prevalence of metastases (PR 4.95, p<0.05). Conclusions: Prostate cancer screening in men aged over 70 may be relevant in Brazil, considering the absence of systematic screening, higher prevalence and higher probability of high-risk disease found in this age range of the population studied.
publishDate 2020
dc.date.none.fl_str_mv 2020-02-01
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1677-55382020000100034
url http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1677-55382020000100034
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv 10.1590/s1677-5538.ibju.2019.0022
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv text/html
dc.publisher.none.fl_str_mv Sociedade Brasileira de Urologia
publisher.none.fl_str_mv Sociedade Brasileira de Urologia
dc.source.none.fl_str_mv International braz j urol v.46 n.1 2020
reponame:International Braz J Urol (Online)
instname:Sociedade Brasileira de Urologia (SBU)
instacron:SBU
instname_str Sociedade Brasileira de Urologia (SBU)
instacron_str SBU
institution SBU
reponame_str International Braz J Urol (Online)
collection International Braz J Urol (Online)
repository.name.fl_str_mv International Braz J Urol (Online) - Sociedade Brasileira de Urologia (SBU)
repository.mail.fl_str_mv ||brazjurol@brazjurol.com.br
_version_ 1750318077246963712